Segment Reporting (Details) $ in Thousands	12 Months Ended
Segment Reporting (Details) $ in Thousands	Dec. 31, 2025 USD ($) segment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Segment Reporting
Number of operating segments \| segment	2
Number of reportable segments \| segment	1
Revenue	$ 176,177	$ 156,769	$ 168,662
Segment Reporting, Other Segment Item, Composition, Description	Other segment items primarily includes professional services, facility allocations, dues and subscriptions, audit fees, insurance, legal fees, and travel expense	Other segment items primarily includes professional services, facility allocations, dues and subscriptions, audit fees, insurance, legal fees, and travel expense	Other segment items primarily includes professional services, facility allocations, dues and subscriptions, audit fees, insurance, legal fees, and travel expense
Adjusted EBITDA for reportable segments	$ 13,087	$ 212	$ 6,032
Investment income	9,798	9,895	10,577
Unrealized loss on investments	1,506	(899)	1,308
Foreign currency loss	12,900	(4,300)	(1,300)
Stock-based compensation expense	(11,032)	(19,704)	(22,808)
Gain on extinguishment of debt, net		18,505	5,679
Impairment loss		(63,809)	(49,569)
Change in fair value of contingent consideration	(5,207)	(1,847)	(890)
Income taxes	(1,799)	(359)	(345)
Loss from continuing operations	(33,969)	(104,708)	(84,559)
Cost, employee related expenses	26,200	23,500	24,800
Cost, depreciation and amortization	8,200	7,600	6,400
Cost, stock-based compensation	1,900	2,600	2,700
Cost, rent	2,500	2,200	2,200
Engineering and development, employee related expenses	10,100	8,900	7,900
Engineering and development, depreciation and amortization	300	400	400
Engineering and development, stock based compensation	600	1,300	1,700
Life Sciences Services
Segment Reporting
Revenue	101,028	85,335	81,188
Cost of revenue	28,285	24,751	27,731
Employee related expenses	53,545	49,820	41,718
Engineering and development expense	3,523	4,933	5,886
Rent	7,643	5,220	5,016
Other segment items	10,369	13,731	15,352
Adjusted EBITDA for reportable segments	(1,220)	(12,480)	(14,163)
Life Sciences Products
Segment Reporting
Revenue	75,149	71,434	87,474
Cost of revenue	30,524	30,565	38,092
Employee related expenses	22,343	20,966	22,830
Engineering and development expense	2,349	2,119	2,230
Rent	765	773	922
Other segment items	5,483	4,860	4,680
Adjusted EBITDA for reportable segments	14,307	12,692	20,195
Operating segments
Segment Reporting
Revenue	177,916	157,950	170,489
Operating segments \| Aggregate of reportable segment
Segment Reporting
Revenue	176,177	156,769	168,662
Operating segments \| Life Sciences Services
Segment Reporting
Revenue	102,145	85,975	81,540
Operating segments \| Life Sciences Products
Segment Reporting
Revenue	75,771	71,975	88,949
Intersegment elimination
Segment Reporting
Revenue	1,739	1,181	1,827
Intersegment elimination \| Life Sciences Services
Segment Reporting
Revenue	1,117	640	352
Intersegment elimination \| Life Sciences Products
Segment Reporting
Revenue	622	541	1,475
Corporate non-segment
Segment Reporting
Corporate overhead costs	(18,866)	(17,983)	(10,147)
Reconciling Items
Segment Reporting
Depreciation and amortization expense	(25,153)	(23,565)	(21,553)
Acquisition and integration costs	(75)	(655)	(6,258)
Cost reduction initiatives	(642)	(842)
Investment income	9,798	9,895	10,577
Unrealized loss on investments	(702)	(5,038)	1,241
Gain on insurance claims			2,642
Other non-recurring costs			(250)
Foreign currency loss	(2,769)	(2,352)	1,355
Interest expense, net	(2,361)	(3,977)	(5,580)
Stock-based compensation expense	(10,066)	(16,567)	(19,824)
Gain on extinguishment of debt, net		18,505	5,679
Impairment loss		(63,809)	(49,569)
Change in fair value of contingent consideration	5,178	1,827	1,441
Income taxes	(1,799)	$ (359)	$ (345)
Other adjustments	$ 401

Cryoport, Inc. 10-K